Breaking News Instant updates and real-time market news.

NKTR

Nektar

$101.44

-0.41 (-0.40%)

, INCY

Incyte

$83.07

-0.91 (-1.08%)

13:14
04/06/18
04/06
13:14
04/06/18
13:14

Mizuho says failure of Incyte's epacadostat ups chances of Nektar takeover

Mizuho analyst Difei Yang raised her price target on Nektar Therapeutics (NKTR) to $103 from $89 after Incyte (INCY) announced this morning the failure of epacadostat in combination with Merck's (MRK) Keytruda in a phase 3 study in melanoma patients. Recent clinical data presented by Nektar reinforced her view of NKTR-214 as one of the most impressive combo agent for checkpoint inhibitors, said Yang, who believes that the failure of epacadostat raises the possibility of a takeout by Bristol-Myers (BMY) in the coming months. She maintains a Buy rating on Nektar shares, which are down 8.5% to $92.75 in afternoon trading.

NKTR

Nektar

$101.44

-0.41 (-0.40%)

INCY

Incyte

$83.07

-0.91 (-1.08%)

MRK

Merck

$54.08

-0.455 (-0.83%)

BMY

Bristol-Myers

$61.47

-0.84 (-1.35%)

  • 06

    Apr

  • 09

    Apr

  • 14

    Apr

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 26

    Apr

  • 01

    May

  • 03

    May

  • 12

    Jun

  • 10

    Jul

  • 23

    Oct

NKTR Nektar
$101.44

-0.41 (-0.40%)

04/02/18
HCWC
04/02/18
INITIATION
Target $125
HCWC
Buy
Nektar assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay assumed coverage of Nektar Therapeutics with a Buy rating and $125 price target. The stock has had a "stellar run, but activity in checkpoint refractory patients could be well received," Chattopadhyay tells investors in a research note. The analyst believes available data from NKTR-214 in combination with Opdivo points to "compelling clinical activity." He sees "significant upside to the stock" beyond what his $125 target suggests should the data hold up to scrutiny.
03/02/18
JPMS
03/02/18
NO CHANGE
Target $90
JPMS
Overweight
Nektar announced another positive update on NKTR-214, says JPMorgan
Nektar Therapeutics last night announced another positive update on NKTR-214 from the phase I dose escalation study and reported additional patients converted to responders, JPMorgan analyst Jessica Fye tells investors in a post-earnings research note. The analyst continues to see NKTR-214, along with the company's immunology/immuno-oncology pipeline, driving potential "significant value creation." She keeps an Overweight rating on Nektar with a $90 price target.
03/02/18
MZHO
03/02/18
NO CHANGE
Target $89
MZHO
Buy
Mizuho has increased conviction in Bristol possibly buying Nektar in 2018
Mizuho analyst Difei Yang believes there is a possibility for Bristol-Myers Squibb (BMY) to acquire Nektar Therapeutics (NKTR) in 2018. The analyst says new positive clinical data of NKTR-214 in combo with Bristol-Myers' Opdivo reinforces her conviction. Bristol-Myers "could make a move" prior to the readouts of Propel study, expected in the second half of 2018, where NKTR-214 was tested in combo with competing products, Tecentiq and Keytruda, Yang tells investors in a research note. The analyst keeps a Buy rating on Nektar with an $89 price target following the company's Q4 results.
03/02/18
ADAM
03/02/18
NO CHANGE
Target $94
ADAM
Buy
Nektar price target raised to $94 from $80 at Canaccord
Canaccord Genuity analyst Arlinda Lee raised her price target for Nektar Therapeutics to $94 after the company reported Q4 results. Notable, Nektar provided a second update to Phase 1 Pivot-2 dose-escalation results indicating ongoing and further tumor shrinkage with improved and continuing response, Lee tells investors in a research note. Further, the company reported 60% response rate in 20 patients with PDL1-negative tumors at baseline, the analyst adds. She believes the update "further solidifies the central positioning" for wholly-owned drug candidate NKTR-214 in combination with anti-PD1. The analyst keeps a Buy rating on Nektar.
INCY Incyte
$83.07

-0.91 (-1.08%)

04/06/18
CANT
04/06/18
NO CHANGE
Target $26
CANT
Overweight
Cantor says premature to assume NewLink trial will fail like Incyte's
NewLink Genetics' (NLNK) indoximod, which acts as a tryptophan mimetic rather than an IDO enzymatic inhibitor, has shown differentiated data versus Incyte's (INCY) epacadostat, Cantor Fitzgerald analyst Mara Goldstein tells investors in a research note. NewLink is trading down 37.5%, or $2.75, to $4.57 after Incyte announced that its ECHO-301 study of epacadostat plus Merck's (MRK) Keytruda versus Keytruda alone was unsuccessful in treating advanced melanoma. Goldstein thinks assuming failure of indoximod "may be premature," but she acknowledges that NewLink shares are likely to be pressured with the company's Phase III trial end likely over a year away. If indoximod is truly differentiated, however, NewLink shares will be higher than $26 given the "now likely limited competition," Goldstein contends. She reiterates an Overweight rating on the shares with a $26 price target.
04/06/18
GUGG
04/06/18
DOWNGRADE
GUGG
Neutral
Incyte downgraded to Neutral from Buy at Guggenheim
04/06/18
WBLR
04/06/18
DOWNGRADE
WBLR
Market Perform
William Blair downgrades Incyte after metastatic melanoma study failure
William Blair analyst Katherine Xu downgraded Incyte (INCY) to Market Perform from Outperform after the company and partner Merck (MRK) announced that ECHO-301 did not meet one of the primary endpoints of improving progression-free survival and that overall survival, the other co-primary endpoint, was not expected to be met either. After taking epacadostat out of her model, the analyst's fair value estimate for Incyte drops to $88 from $170. The stock in premarket trading is down 21%, or $17.08, to $65.99. It is unclear whether the biomarker data derived from ECHO-301 could guide other Phase III studies, and whether the other Phase III studies are to continue, Xu tells investors in a research note. She sees the next key catalysts for Incyte shares as the baricitinib advisory panel on April 23, and data from Jakafi Phase II pivotal REACH1 study in steroid-refractory acute graft-versus-host disease in the first half 2018.
04/06/18
04/06/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Incyte (INCY) downgraded to Neutral from Buy at Guggenheim and to Market Perform from Outperform at William Blair. 2. Ormat Technologies (ORA) downgraded to Perform from Outperform at Oppenheimer with analyst Noah Kaye citing valuation. 3. Sprague Resources (SRLP) downgraded to Underweight from Neutral at JPMorgan with analyst Andrew Burd citing the stock's year-to-date outperformance for the downgrade. 4. Banc of California (BANC) downgraded to Underperform from Neutral at BofA/Merrill with analyst Ebrahim Poonwala saying the company's new management team is working towards achieving its long-term strategic targets but is cautious on elevated execution risk given the balance sheet overhaul and lower quality deposit base. 5. Xilinx (XLNX) downgraded to Underweight from Neutral at JPMorgan with analyst Harlan Sur saying he believes multiple compression is likely with basestation deployment in China likely to decline in 2018. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MRK Merck
$54.08

-0.455 (-0.83%)

04/05/18
LEHM
04/05/18
NO CHANGE
LEHM
Barclays upgrades Merck, downgrades Biogen and Pfizer in sector reassessment
Barclays analyst Geoff Meacham made some rating changes while reassessing the Biopharmaceutical sector. Biopharma sentiment has been negative since the start of 2018, despite a modest pick-up in deals and diminished rhetoric on drug pricing, Meacham tells investors in a research note titled "U.S. Biopharmaceuticals: Where to from here?" The analyst believes "more transformative" acquisitions, "clean" Phase 3 wins, and even a relatively strong Q1 earnings season could help "re-rate the sector" and get investors more engaged in the group. Ahead of the Q1 earnings season, Meacham upgraded Merck (MRK) to Overweight from Equal Weight and downgraded to Equal Weight from Overweight shares of Biogen (BIIB), Pfizer (PFE), Biohaven Pharmaceutical (BHVN) and Myovant Sciences (MYOV). The analyst also lowered his price target for Equal Weight-rated AbbVie (ABBV) to $102 from $120, for Equal Weight-rated Amgen (AMGN) to $180 from $180, for Overweight-rated Prothena (PRTA) to $50 from $70 and for Overweight-rated Incyte (INCY) to $135 from $165.
04/05/18
04/05/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Overweight from Equal Weight at Barclays with analyst Geoffrey Meacham saying he believes the company will continue to take share in first-line lung cancer, driven by positive KN-189 and KN-042 data. 2. Acuity Brands (AYI) upgraded to Outperform from Market Perform at JMP Securities with analyst Joseph Osha saying he believes the stock is finally trading at a "reasonable valuation based on reasonable expectations." 3. AMD (AMD) upgraded to Buy from Hold at Stifel with analyst Kevin Cassidy citing valuation and the company's margin expansion potential. 4. Tiffany (TIF) upgraded to Buy from Hold at Loop Capital with analyst Laura Champine saying her initial meeting with the company's new CEO Alessandro Bogliogo added to her confidence. 5. Citi (C) and Wells Fargo (WFC) were upgraded to Buy from Neutral at UBS. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BMY Bristol-Myers
$61.47

-0.84 (-1.35%)

03/20/18
JPMS
03/20/18
NO CHANGE
Target $75
JPMS
Overweight
Bristol-Myers price target raised to $75 from $70 at JPMorgan
JPMorgan analyst Chris Schott raised his price target for Bristol-Myers Squibb to $75 saying the company's opportunity in non-lung tumor types is broad and underappreciated. The analyst sees a number of $1B-plus indications for Opdivo beyond non-small-cell lung carcinoma, including kidney, liver, gastric, small cell lung and melanoma. These indications should represent the majority of Opdivo sales over time, Schott tells investors in a research note. The analyst keeps an Overweight rating on Bristol-Myers.
03/12/18
LEER
03/12/18
UPGRADE
Target $66
LEER
Outperform
Leerink upgrades Merck to Outperform ahead of KN-189 presentation
Leerink analyst Seamus Fernandez upgraded Merck (MRK) to Outperform from Market Perform with an unchanged price target of $66. The shares closed Friday up 38c to $55.14. Keytruda will continue to dominate the first-line non-small cell lung cancer market, Fernandez tells investors in a research note. Following his firm's lung cancer survey, the analyst believes Merck will deliver upside to consensus Keytruda estimates along with positive earnings leverage in the second half of 2018 and 2019. He thinks KN-189 likely will show a clinically meaningful overall survival benefit for the Keytruda plus chemo combo in all patients, including a strong benefit in patients with moderate or low PD-L1 biomarker levels. Fernandez does not believe Bristol-Myers' (BMY) Opdivo and Yervoy combo will supplant Keytruda as the market leader. The analyst thinks now is the time to own shares of Merck.
02/20/18
JEFF
02/20/18
INITIATION
Target $61
JEFF
Buy
Armo BioSciences initiated with a Buy at Jefferies
Jefferies analyst Biren Amin started Armo BioSciences (ARMO) with a Buy rating and $61 price target. The analyst thinks the shares will trade on potential for AM0010, an IL-10 cytokine. The data in non-small-cell lung carcinoma show "encouraging signals" and the pancreatic cancer data suggest better activity than chemo alone, Amin tells investors in a research note. He notes cytokines have recently garnered interest after Nektar Therapeutics (NKTR) inked a partnership with Bristol-Myers (BMY) for a $1.8B upfront.

TODAY'S FREE FLY STORIES

PDVW

pdvWireless

$39.84

0.06 (0.15%)

16:30
11/17/18
11/17
16:30
11/17/18
16:30
Conference/Events
pdvWireless management to meet with Morgan Stanley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBS

CBS

$57.49

0.23 (0.40%)

16:28
11/17/18
11/17
16:28
11/17/18
16:28
Conference/Events
CBS management to meet with Morgan Stanley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

THS

TreeHouse

$51.92

0.72 (1.41%)

, CAG

Conagra Brands

$33.09

0.66 (2.04%)

12:54
11/17/18
11/17
12:54
11/17/18
12:54
Periodicals
Treehouse Foods stock may have room to gain, Barron's says »

Treehouse Foods (THS)…

THS

TreeHouse

$51.92

0.72 (1.41%)

CAG

Conagra Brands

$33.09

0.66 (2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$194.23

1.83 (0.95%)

12:51
11/17/18
11/17
12:51
11/17/18
12:51
Periodicals
Amgen may be 'a remedy' for tougher times, Barron's says »

Amgen may be a stock that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 01

    Dec

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

AAPL

Apple

$193.42

2 (1.04%)

, LITE

Lumentum

$41.50

0.46 (1.12%)

12:47
11/17/18
11/17
12:47
11/17/18
12:47
Periodicals
Apple stock could continue to slide, Barron's says »

Apple's (AAPL) stock…

AAPL

Apple

$193.42

2 (1.04%)

LITE

Lumentum

$41.50

0.46 (1.12%)

QRVO

Qorvo

$66.32

1.18 (1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$56.39

0.9 (1.62%)

, RDS.B

Royal Dutch Shell

$63.97

0.19 (0.30%)

12:41
11/17/18
11/17
12:41
11/17/18
12:41
Periodicals
Investors may find bargains among oil, natural gas stocks, Barron's says »

Investors have been…

APC

Anadarko

$56.39

0.9 (1.62%)

RDS.B

Royal Dutch Shell

$63.97

0.19 (0.30%)

RDS.A

Royal Dutch Shell

$62.02

0.34 (0.55%)

XOM

Exxon Mobil

$78.99

0.81 (1.04%)

CVX

Chevron

$119.14

2.18 (1.86%)

BP

BP

$40.85

-0.3 (-0.73%)

EOG

EOG Resources

$105.21

3.57 (3.51%)

OXY

Occidental Petroleum

$73.32

0.71 (0.98%)

COG

Cabot Oil & Gas

$25.73

0.09 (0.35%)

EQT

EQT Corporation

$16.62

-0.55 (-3.20%)

HAL

Halliburton

$32.46

0.02 (0.06%)

SLB

Schlumberger

$48.24

0.17 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 18

    Jan

  • 22

    Jan

LB

L Brands

$35.28

-0.41 (-1.15%)

, JCP

J.C. Penney

$1.29

-0.08 (-5.84%)

12:34
11/17/18
11/17
12:34
11/17/18
12:34
Periodicals
Kohl's, Target set to thrive this holiday season, Barron's says »

Store chains have been…

LB

L Brands

$35.28

-0.41 (-1.15%)

JCP

J.C. Penney

$1.29

-0.08 (-5.84%)

TJX

TJX

$51.47

-0.98 (-1.87%)

BBY

Best Buy

$66.41

-1.34 (-1.98%)

TIF

Tiffany

$106.48

0.52 (0.49%)

HD

Home Depot

$177.11

-0.25 (-0.14%)

TGT

Target

$79.67

-1.09 (-1.35%)

KSS

Kohl's

$72.48

-0.7 (-0.96%)

AMZN

Amazon.com

$1,593.59

-26.41 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 28

    Nov

  • 04

    Dec

  • 05

    Dec

  • 03

    Mar

T

AT&T

$30.30

0.18 (0.60%)

, FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

09:18
11/17/18
11/17
09:18
11/17/18
09:18
OnTheFly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

T

AT&T

$30.30

0.18 (0.60%)

FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

FOXA

21st Century Fox

$48.18

-0.11 (-0.23%)

AMZN

Amazon.com

$1,593.59

-26.41 (-1.63%)

CMCSA

Comcast

$38.60

0.11 (0.29%)

CMCSK

Comcast

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$16.46

-0.12 (-0.72%)

F

Ford

$9.05

-0.26 (-2.79%)

GM

General Motors

$35.76

0.21 (0.59%)

HMC

Honda

$28.21

0.01 (0.04%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$116.87

-0.02 (-0.02%)

VLKAY

Volkswagen

$0.00

(0.00%)

NYT

New York Times

$26.30

-0.2 (-0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 03

    Dec

  • 04

    Dec

  • 13

    Dec

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

NVS

Novartis

$87.74

0.52 (0.60%)

, DBVT

DBV Technologies

$16.70

0.31 (1.89%)

04:55
11/17/18
11/17
04:55
11/17/18
04:55
Conference/Events
American College of Allergy, Asthma & Immunology to hold a meeting »

2018 ACAAI Meeting will…

NVS

Novartis

$87.74

0.52 (0.60%)

DBVT

DBV Technologies

$16.70

0.31 (1.89%)

REGN

Regeneron

$345.10

3.56 (1.04%)

SHPG

Shire

$175.59

-3.39 (-1.89%)

TEVA

Teva

$22.25

-0.37 (-1.64%)

SNY

Sanofi

$45.11

0.56 (1.26%)

GSK

GlaxoSmithKline

$40.35

-0.06 (-0.15%)

AZN

AstraZeneca

$40.67

-0.685 (-1.66%)

CHD

Church & Dwight

$65.42

-0.39 (-0.59%)

BSX

Boston Scientific

$37.22

0.75 (2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 30

    Nov

  • 02

    Dec

  • 03

    Dec

  • 21

    Dec

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

  • 13

    May

MSI

Motorola Solutions

$129.97

0.72 (0.56%)

18:48
11/16/18
11/16
18:48
11/16/18
18:48
Hot Stocks
Motorola Solutions: ITC confirms Hytera products infringe Motorola patents »

Motorola Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 18

    Dec

  • 19

    Dec

PCG

PG&E

$24.39

6.62 (37.25%)

18:23
11/16/18
11/16
18:23
11/16/18
18:23
Periodicals
CPUC isn't ruling out board shuffle, breakup for PG&E, Bloomberg says »

The California Public…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABX

Barrick Gold

$13.04

0.05 (0.38%)

18:00
11/16/18
11/16
18:00
11/16/18
18:00
Periodicals
Barrick Gold looking to add more copper, bullion assets, Reuters reports »

Barrick Gold is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTR

Aqua America

$33.05

0.165 (0.50%)

17:57
11/16/18
11/16
17:57
11/16/18
17:57
Hot Stocks
Aqua America CEO acquires over 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRE

Real Estate SPDR

$33.45

0.445 (1.35%)

, XLB

S&P Select Materials SPDR

$55.23

0.53 (0.97%)

17:39
11/16/18
11/16
17:39
11/16/18
17:39
General news
Week ending ETF scorecard: Real Estate leads, Consumer Discretionary slumps »

S&P500 SECTORS: Real…

XLRE

Real Estate SPDR

$33.45

0.445 (1.35%)

XLB

S&P Select Materials SPDR

$55.23

0.53 (0.97%)

XLU

Utilities SPDR

$54.86

0.77 (1.42%)

XLI

Industrial Select Sector SPDR

$72.00

(0.00%)

XLV

Health Care Select Sector SPDR

$92.05

0.91 (1.00%)

XLF

Financial Select Sector

$26.78

0.03 (0.11%)

XLP

Consumer Staples Sector SPDR

$56.04

0.15 (0.27%)

XLE

Energy Select Sector SPDR

$67.23

0.76 (1.14%)

XLC

Communication Services Select Sector SPDR Fund

$44.88

-0.2 (-0.44%)

XLK

Technology Select Sector SPDR

$68.22

-0.1 (-0.15%)

XLY

Consumer Discretionary Sector SPDR

$106.37

-0.43 (-0.40%)

GLD

SPDR Gold Shares

$115.56

0.82 (0.71%)

SLV

iShares Silver Trust

$13.55

0.115 (0.86%)

USO

United States Oil Fund

$12.07

0.08 (0.67%)

UNG

United States Natural Gas Fund

$35.43

3.63 (11.42%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$83.24

-0.27 (-0.32%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$111.73

0.23 (0.21%)

TLT

iShares 20+ Year Treasury Bond Fund

$114.65

0.61 (0.53%)

IEF

iShares 7-10 Year Treasury Bond ETF

$101.13

0.3 (0.30%)

SHY

iShares 1-3 Year Treasury Bond

$83.13

0.08 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQST

Aquestive Therapeutics

$17.02

0.23 (1.37%)

17:36
11/16/18
11/16
17:36
11/16/18
17:36
Hot Stocks
Aquestive receives CRL from FDA for tadalafil oral film »

Aquestive Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

DAKT

Daktronics

$7.67

0.07 (0.92%)

17:35
11/16/18
11/16
17:35
11/16/18
17:35
Hot Stocks
Daktronics adopts new shareholder rights agreement »

Daktronics announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

TI

Telecom Italia

$6.02

0.12 (2.03%)

17:33
11/16/18
11/16
17:33
11/16/18
17:33
Periodicals
Gubitosi viewed as frontrunner for Telecom Italia CEO job, Reuters says »

Veteran Italian manager…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAXR

Maxar Technologies

$18.77

-0.59 (-3.05%)

17:30
11/16/18
11/16
17:30
11/16/18
17:30
Hot Stocks
Maxar Technologies shareholders approve U.S. domestication »

Maxar Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLUG

Plug Power

$1.83

(0.00%)

17:28
11/16/18
11/16
17:28
11/16/18
17:28
Syndicate
Breaking Syndicate news story on Plug Power »

Plug Power files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSB

GlobalSCAPE

$4.55

-0.02 (-0.44%)

17:22
11/16/18
11/16
17:22
11/16/18
17:22
Syndicate
Breaking Syndicate news story on GlobalSCAPE »

GlobalSCAPE files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQIX

Equinix

$388.18

2.67 (0.69%)

17:19
11/16/18
11/16
17:19
11/16/18
17:19
Hot Stocks
Equinix's Lee sells 2,792 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 10

    Dec

LMT

Lockheed Martin

$301.06

-4.42 (-1.45%)

17:17
11/16/18
11/16
17:17
11/16/18
17:17
Hot Stocks
Lockheed Martin awarded $282.09M Naval Sea Systems Command contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLGT

Teligent

$2.56

0.045 (1.79%)

17:16
11/16/18
11/16
17:16
11/16/18
17:16
Hot Stocks
Teligent receives notification of deficiency from Nasdaq »

Teligent said that on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STAF

Staffing 360 Solutions

$1.82

0.07 (4.00%)

17:16
11/16/18
11/16
17:16
11/16/18
17:16
Syndicate
Breaking Syndicate news story on Staffing 360 Solutions »

Staffing 360 Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

IMMR

Immersion

$9.56

-0.14 (-1.44%)

17:12
11/16/18
11/16
17:12
11/16/18
17:12
Hot Stocks
Breaking Hot Stocks news story on Immersion »

Man Group reports 4.84%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.